+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 153 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
M

Actively Recruiting

Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.

Age: 18Years +All GendersPhase 2
64 locations
R

Actively Recruiting

This research investigates a new self-administered digital application designed to improve sexual health, quality of life, and psychological distress among survivors of hematopoietic stem cell transplants HCT. HCT survivors often face long-term sexual dysfunction due to complex biological, psychological, and social factors, which significantly affect their well-being and relationships. The study aims to address these challenges through a multidisciplinary approach delivered via a digital platform. Participants will be randomly assigned to either use the SHIFT digital application or receive enhanced usual care. The SHIFT app includes interactive features like gamification, survivor videos, intimacy exercises, and optional content to engage users over eight weeks. Those in the usual care group will meet with their clinicians and may be referred to specialists if needed but will not have access to the SHIFT app. During the study, participants will complete assessments measuring sexual satisfaction, function, quality of life, anxiety, and depression at various points up to 24 weeks. Researchers will monitor global satisfaction with sex at week 8 as the primary outcome. The study involves medical evaluations and tracks psychological and physical health through questionnaires and scales, aiming to evaluate the impact of the digital intervention on sexual health outcomes and overall well-being in HCT survivors.

Age: 18Years +All GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are evaluating a new treatment approach for adults aged 18 to 75 years with newly diagnosed acute myeloid leukemia AML that has specific genetic changes in the NPM1, MLLKMT2A, or NUP98 genes. This phase Ib trial aims to find the best dose and assess the safety of the drug revumenib SNDX-5613 when combined with standard chemotherapy drugs daunorubicin and cytarabine. The study focuses on patients who can tolerate intensive chemotherapy and have untreated AML. Participants receive revumenib orally twice daily alongside daunorubicin given intravenously for 1 to 3 days and cytarabine given as a continuous infusion or intermittent intravenous infusion depending on the treatment phase. Treatment includes an induction phase, possible re-induction for persistent disease, and consolidation cycles repeated every 42 days up to three times if tolerated. During treatment, patients undergo heart function scans, bone marrow biopsies, and blood tests at scheduled times to monitor response and safety. Throughout the study, patients are closely monitored through clinical assessments, including pharmacokinetic studies of revumenib and evaluations of leukemia cell response. After completing treatment, participants are followed for up to two years or until relapse or death. Researchers measure the recommended dose for further study, complete response rates, and other important outcomes such as measurable residual disease and potential biomarkers related to treatment response.

Age: 18Years - 75YearsAll GendersPhase 1
23 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
R

Actively Recruiting

Researchers are evaluating treatments for patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms MPNs. This phase II trial compares ASTX727, a combination of cedazuridine and decitabine, given alone or combined with iadademstat. The study aims to assess how these treatments affect leukemia response rates and survival outcomes in patients who have not previously received certain DNA methyltransferase inhibitors. Patients are assigned to one of two groups. One group receives ASTX727 orally once daily on days 1 to 5 of each 28-day cycle. The other group receives the same ASTX727 schedule plus iadademstat orally on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Treatment continues until disease progression or unacceptable side effects occur. Throughout the trial, researchers collect blood, buccal swab, and bone marrow samples to study the disease and treatment effects. Participants have regular assessments including blood tests, bone marrow biopsies, and sample collections over the treatment period. After stopping treatment for reasons other than disease progression, they are followed every 3 months if they stop due to progression, follow-up occurs every 6 months. The main outcome measured is the acute leukemia response rate within 4 treatment cycles. Secondary outcomes include event-free survival, overall survival, and the rate of stem cell transplantation over two years.

Age: 18Years +All GendersPhase 2
32 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
C

Actively Recruiting

Researchers are evaluating AZD0120, a dual-targeted CAR-T cell therapy against BCMA and CD19, compared with standard treatment regimens in people with relapsed refractory multiple myeloma RRMM. This Phase III open-label, randomized global trial aims to compare the effectiveness and safety of AZD0120 against four standard regimens DKd daratumumab, carfilzomib, dexamethasone, DPd daratumumab, pomalidomide, dexamethasone, PVd pomalidomide, bortezomib, dexamethasone, and Kd carfilzomib, dexamethasone. Participants will be randomly assigned to receive either AZD0120 or one of the four standard regimens chosen by their investigator. AZD0120 is a biological CAR-T cell therapy, while the standard regimens involve combinations of drugs administered according to routine care. The study evaluates treatment effectiveness over several years, including progression-free survival and minimal residual disease negativity. During the trial, participants will undergo regular assessments including laboratory tests and clinical evaluations to monitor disease status and treatment response. Key outcomes include progression-free survival and minimal residual disease negativity rates. Safety and effectiveness will be monitored over multiple years. The total study duration extends up to 5 years, with participants followed for outcomes such as overall survival and response rates.

Age: 18Years +All GendersPhase 3
143 locations
A

Actively Recruiting

Researchers are evaluating KB803, an ophthalmic suspension containing a modified herpes simplex virus expressing human collagen VII protein, in patients with dystrophic epidermolysis bullosa DEB who experience recurrent corneal abrasions. This Phase 3, double-blind, randomized, placebo-controlled crossover study aims to assess the safety and effectiveness of KB803 compared to a matched placebo in both children and adults with DEB. The study is sponsored by Krystal Biotech, Inc. Participants who have been in the Sponsors natural history study for at least 12 weeks and meet other criteria will be randomly assigned to receive either KB803 or placebo eye drops three times a week for the first 12 weeks. Then, they will switch to the alternate treatment for another 12 weeks. The eye treatments are given at home by a trained person, with monitoring by the study team. During the 24-week study, researchers will monitor safety and tolerability, track the frequency of corneal abrasion symptoms, and assess eye pain. Participants or their guardians will keep weekly symptom diaries and complete monthly questionnaires about symptoms and disease severity. Study staff will regularly check for any side effects or changes in treatment. The total participation lasts 24 weeks with ongoing safety and symptom evaluations.

Age: 6Months +All GendersPhase 3
5 locations

1-10 of 153

1